A major patient-level meta-analysis published in The Lancet reveals that ovarian ablation or suppression significantly lowers the 15-year risk of recurrence and death for premenopausal women with estrogen-receptor-positive early breast cancer. The finding holds true even when patients have already received chemotherapy or tamoxifen. Researchers pooled data from 23 randomized trials involving 15,000 women worldwide.
These results challenge the prevailing notion that ovarian suppression offers limited additional benefit beyond standard endocrine therapies. The analysis suggests younger women with hormone-sensitive tumors stand to gain substantially from this intervention, potentially reshaping treatment guidelines. Experts caution, however, that the benefits must be weighed against side effects like menopausal symptoms and bone density loss.
The meta-analysis found that ovarian function suppression reduced the 15-year recurrence risk by a statistically significant margin—though the exact percentage reduction was not specified in the source. Both recurrence and breast cancer mortality were lower in the treatment group across all ages and chemotherapy regimens included. The data reinforce the value of combined endocrine approaches for this patient population.
Clinicians may now need to reconsider offering ovarian suppression alongside standard therapy for high-risk premenopausal patients. The findings could prompt updated recommendations from bodies like the National Comprehensive Cancer Network. Future research should focus on identifying which subgroups benefit most and managing treatment-related quality-of-life impacts.
Some oncologists argue that modern chemotherapy already achieves adequate ovarian suppression in many women, questioning the added value of surgical or radiation-based ablation. The study authors note that individual patient preferences and risk profiles remain critical in treatment decisions.